Anti-PD-1 mAb

About CSPC Innovation Pharmaceutical

CSPC Innovation Pharmaceutical's mission is to establish CSPC as a global, innovation-driven biopharmaceutical leader by developing and commercializing novel therapeutics. Its key achievement is building a substantial and maturing clinical pipeline, primarily in oncology, which is now advancing into late-stage trials and contributing to the parent group's valuation of over $45 billion. The strategy centers on leveraging internal R&D across multiple modalities, strategic external partnerships, and the parent company's formidable commercial and manufacturing scale to efficiently bring differentiated medicines to the large Chinese and international markets.

Therapeutic Areas